Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon.
AUTOR(ES)
Hartshorn, K L
RESUMO
Both recombinant alpha A interferon and azidothymidine inhibit the replication of human immunodeficiency virus in peripheral blood mononuclear cells. Combinations of recombinant alpha A interferon and azidothymidine at concentrations that are easily achievable in patients synergistically inhibit human immunodeficiency virus in vitro with minimal toxicity. Combinations of antiretroviral compounds that act by different mechanisms may prove useful in the treatment of acquired immunodeficiency syndrome-related disorders.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=174685Documentos Relacionados
- Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon.
- Inhibition of human immunodeficiency virus type 1 morphogenesis in T cells by alpha interferon.
- Synergistic inhibition of human immunodeficiency virus type 1 replication by 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU) and azidothymidine in vitro.
- Inhibition of hepatitis B virus in tissue culture by alpha interferon.
- Synergistic inhibition of human cytomegalovirus replication by interferon-alpha/beta and interferon-gamma
